Pyxis Oncology (NASDAQ:PYXS) Stock Price Up 3.6% - Time to Buy?

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report)'s share price rose 3.6% during trading on Monday . The company traded as high as $1.16 and last traded at $1.14. Approximately 617,104 shares traded hands during mid-day trading, a decline of 16% from the average daily volume of 734,339 shares. The stock had previously closed at $1.10.

Wall Street Analysts Forecast Growth

PYXS has been the subject of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Pyxis Oncology in a report on Monday, May 19th. Royal Bank Of Canada reissued an "outperform" rating and issued a $8.00 target price on shares of Pyxis Oncology in a report on Wednesday, March 19th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $9.00.

Pyxis Oncology Trading Up 3.6%

The firm has a market cap of $70.62 million, a price-to-earnings ratio of -0.72 and a beta of 1.13. The firm has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.24.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, equities analysts expect that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PYXS. Commonwealth Equity Services LLC raised its stake in Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock valued at $41,000 after purchasing an additional 10,000 shares during the last quarter. American Century Companies Inc. raised its stake in Pyxis Oncology by 88.1% in the 4th quarter. American Century Companies Inc. now owns 299,937 shares of the company's stock valued at $468,000 after purchasing an additional 140,498 shares during the last quarter. Sei Investments Co. acquired a new position in Pyxis Oncology in the 4th quarter valued at about $95,000. Aristides Capital LLC acquired a new position in Pyxis Oncology in the 4th quarter valued at about $193,000. Finally, Renaissance Technologies LLC raised its stake in Pyxis Oncology by 83.0% in the 4th quarter. Renaissance Technologies LLC now owns 293,354 shares of the company's stock valued at $458,000 after purchasing an additional 133,018 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.